Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The researchers evaluated the impact of nicotinic agonists compared to nicotine replacement therapy (NRT) on opioid and cigarette use.

Who Took Part

The abstract describes 97 participants taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The researchers conducted a secondary analysis of the St PETER HIV study, a randomized, double-blinded, placebo-controlled trial of 400 HIV-positive individuals recruited from July 2017 to December 2020 at HIV care sites in St.

Their analysis focused on the 97 participants who reported opioid use at baseline.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

Logistic regression assessed the relationship between treatment arms and their primary outcome of self-reported opioid use.

Hochberg-adjusted p-values accounted for multiple comparisons.

What Was Measured

The researchers evaluated the impact of nicotinic agonists compared to nicotine replacement therapy (NRT) on opioid and cigarette use.

PubMed files the paper under topics including Nicotinic Agonists, Nicotine Replacement Therapy, Varenicline, Opioid-Related Disorders, Cigarette Smoking, HIV Infections and Tobacco Use Disorder.

The authors tagged it with the keywords Co-treatment, Nicotinic partial agonist, Opioid use disorder and Smoking cessation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 97 participants.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Journal of substance use and addiction treatment), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.